Pb2362: the effect of body mass index (bmi) on the prognosis of dlbcl patients treated with r-chop: a real world moroccan experience

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The correlation between body mass index (BMI) and outcome of diffuse large B-cell lymphoma (DLBCL) is still debated in some studies. To clarify this relationship, we performed this study to examine the overall survival (OS) and progression-free survival (PFS) of DLBCL patients classified as overweight (BMI between 25 and <30kg/m2), obese (BMI of 30kg/m2 or more), underweight (BMI less than 18.5kg/m2), or normal weight (BMI between 18.5 and <25kg/m2). Aims: We retrospectively compared the outcomes of DLBCL patients treated with R-CHOP at our center according to BMI. Methods: We conducted a retrospective analysis of moroccan patients diagnosed with DLBCL and treated with R-CHOP from January 2010 to January 2021. The analysis only included patients with a calculated BMI. Demographic, prognostic, and therapeutic information was collected, Survival outcomes were analyzed using the summary hazard ratio (HR) and a 95% confidence interval (CI). Results: In the study, 140 subjects were included, and their age, performance score, international prognostic index, B-symptoms, and extranodal involvement were similar and comparable between the two groups. The analysis showed that the overall survival (OS) of the overweight group was better than that of the normal weight group. However, no association was found in obese patients. Similarly, neither obesity nor overweight significantly impacted progression-free survival (PFS) in DLBCL. However, underweight patients had worse OS and PFS than the normal weight group. Summary/Conclusion: In DLBCL, patients who are overweight have a better survival rate compared to those who are of normal weight, whereas underweight patients have a poorer survival rate. Keywords: DLBCL, Prognostic factor, Rituximab